Risultati per: Nuovo test rapido per distinguere le infezioni virali

Sarà sfruttata la sensoristica all’avanguardia insieme all’intelligenza artificiale.

Introduction
Chimeric antigen receptor (CAR) T-cell therapies are novel, potentially curative therapies for haematological malignancies. CAR T-cell therapies are associated with severe toxicities, meaning patients require monitoring during acute and postacute treatment phases. Electronic patient-reported outcomes (ePROs), self-reports of health status provided via online questionnaires, can complement clinician observation with potential to improve patient outcomes. This study will develop and evaluate feasibility of a new ePRO system for CAR-T patients in routine care.

Methods and analysis
Multiphase, mixed-methods study involving multiple stakeholder groups (patients, family members, carers, clinicians, academics/researchers and policy-makers). The intervention development phase comprises a Delphi study to select PRO measures for the digital system, a codesign workshop and consensus meetings to establish thresholds for notifications to the clinical team if a patient reports severe symptoms or side effects. Usability testing will evaluate how users interact with the digital system and, lastly, we will evaluate ePRO system feasibility with 30 CAR-T patients (adults aged 18+ years) when used in addition to usual care. Feasibility study participants will use the ePRO system to submit self-reports of symptoms, treatment tolerability and quality of life at specific time points. The CAR-T clinical team will respond to system notifications triggered by patients’ submitted responses with actions in line with standard clinical practice. Feasibility measures will be collected at prespecified time points following CAR T-cell infusion. A qualitative substudy involving patients and clinical team members will explore acceptability of the ePRO system.

Ethics and dissemination
Favourable ethical opinion was granted by the Health and Social Care Research Ethics Committee B(HSC REC B) (ref: 23/NI/0104) on 28 September 2023. Findings will be submitted for publication in high-quality, peer-reviewed journals. Summaries of results, codeveloped with the Blood and Transplant Research Unit Patient and Public Involvement and Engagement group, will be disseminated to all interested groups.

Trial registration number
ISCTRN11232653.

Si prevede che il numero di casi nel 2024 supererà i numeri già elevati dello scorso anno, mentre cresce la preoccupazione che la forma più grave e potenzialmente mortale continuerà a diffondersi. C’è il rischio di una nuova pandemia?

Oncologi, nuove cure e esami specifici migliorano sopravvivenza

Current test performance characteristics of blood-based colorectal cancer screening tests are insufficient to justify their high costs compared with less expensive and more effective alternatives such as fecal immunochemical testing, triennial stool DNA testing combined with a fecal immunochemical testing assay, and colonoscopy.

Results from a model involving 48 proteins and 43 metabolites as well as age, sex, and systolic blood pressure might indicate that a person is at increased risk for a myocardial infarction, or heart attack, within the next 6 months, according to a cohort study involving more than 2000 people in Europe. The ability to forecast someone’s short-term risk “may enhance the motivation of patients and doctors for primary prevention,” the researchers reported in Nature Cardiovascular Research.

New England, prove da uno studio su 8000 individui

Balzanelli, sperimentazione con assistenza tecnologica di Caltec

New England Journal of Medicine, Ahead of Print.

Vaia, ‘da noi nessun allarme ma potenziamo le azioni di vigilanza’

Performance of the new version was examined in 20,000 people who were undergoing screening colonoscopy.

This test detected 88% of early-stage colorectal cancers but sensitivity for advanced precancerous lesions was low.

New England Journal of Medicine, Volume 390, Issue 11, Page 973-983, March 2024.

New England Journal of Medicine, Volume 390, Issue 11, Page 984-993, March 2024.

Researchers have begun studying how accurately a new tool, known as the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator, estimates risk in people from different racial and ethnic backgrounds as well as from a range of ages, the American Heart Association announced. Three research teams will evaluate the new scores using larger databases and will assess PREVENT’s fairness and cost-effectiveness compared with the Pooled Cohort Equations (PCEs).

Una nuova circolare a quasi un mese dalla prima diffusa dalla direzione della Prevenzione del ministero della Salute